These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21140203)

  • 1. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
    Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S
    Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
    Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
    Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
    Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
    Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
    Shima K; Nosho K; Baba Y; Cantor M; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Int J Cancer; 2011 Mar; 128(5):1080-94. PubMed ID: 20473920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
    Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
    Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD
    PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.
    Nagasaka T; Goel A; Notohara K; Takahata T; Sasamoto H; Uchida T; Nishida N; Tanaka N; Boland CR; Matsubara N
    Int J Cancer; 2008 Jun; 122(11):2429-36. PubMed ID: 18240147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
    Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
    World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
    Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
    Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.
    Hawkins NJ; Lee JH; Wong JJ; Kwok CT; Ward RL; Hitchins MP
    Mod Pathol; 2009 Dec; 22(12):1588-99. PubMed ID: 19734844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.
    Rosty C; Young JP; Walsh MD; Clendenning M; Walters RJ; Pearson S; Pavluk E; Nagler B; Pakenas D; Jass JR; Jenkins MA; Win AK; Southey MC; Parry S; Hopper JL; Giles GG; Williamson E; English DR; Buchanan DD
    Mod Pathol; 2013 Jun; 26(6):825-34. PubMed ID: 23348904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
    Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
    Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.